Abstract
Biologic agents are increasingly being used in the management of a variety of inflammatory, autoimmune, cancer, and transplant conditions. Its use predisposes individuals to a diversity of pulmonary side effects that can manifest as pulmonary infiltrates. Most common causes of pulmonary infiltrates are infectious. Although bacterial pneumonia still needs to be considered first, there are increased reports of invasive fungal infections (Aspergillus, Pneumocystis, and endemic fungi) and mycobacterial infections presenting with pulmonary infiltrates after the use of biologic agents. Screening for latent tuberculosis is now common practice prior to starting biologic agents that increase the risk of this disease. Noninfectious etiology includes worsening of the underlying lung disease in patients with autoimmune disease and drug toxicity. Pulmonary infiltrates in patients receiving biologic agents are commonly life-threatening and need urgent diagnosis and management. This chapter addresses the most common causes of pulmonary infiltrates in patients receiving biologics and the diagnostic approach to pulmonary infiltrates.
| Original language | English (US) |
|---|---|
| Title of host publication | Infectious Complications in Biologic and Targeted Therapies |
| Publisher | Springer International Publishing |
| Pages | 335-350 |
| Number of pages | 16 |
| ISBN (Electronic) | 9783031113635 |
| ISBN (Print) | 9783031113628 |
| DOIs | |
| State | Published - Jan 1 2022 |
Bibliographical note
Publisher Copyright:© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.
Keywords
- Bacterial pneumonia
- Drug-induced pulmonary toxicity
- Fungal infections
- Management
- Mycobacterial infections
- Prevention
- Respiratory viruses
